Richard R.  Deluca net worth and biography

Richard Deluca Biography and Net Worth

Rick DeLuca is executive vice president and president, Animal Health for Merck.​ Rick has worldwide responsibility for the Animal Health business, a position he has held since 2011. Under Rick’s leadership, Merck’s Animal Health business has become an industry leader that offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products.

Prior to joining Merck, Rick spent more than two decades in positions of increasing scope and responsibility at Wyeth, including president of Animal Health, chief operating officer and chief financial officer of Animal Health, vice president of finance global pharmaceuticals and director audit. He was also a member of Wyeth’s executive, operations, law and regulatory and human resources and benefits committees.​

Rick was board chairman of Health for Animals, the global animal health industry association, from 2017 to 2020. He is also board chairman of Animal Health Institute, the U.S. animal medicines industry association, a position he has held since 2016. ​Rick received his B.A. in business administration from Widener University. He is a certified public accountant and certified management accountant.

What is Richard R. Deluca's net worth?

The estimated net worth of Richard R. Deluca is at least $14.59 million as of November 8th, 2023. Mr. Deluca owns 111,764 shares of Merck & Co., Inc. stock worth more than $14,591,908 as of June 21st. This net worth evaluation does not reflect any other investments that Mr. Deluca may own. Learn More about Richard R. Deluca's net worth.

How do I contact Richard R. Deluca?

The corporate mailing address for Mr. Deluca and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Richard R. Deluca's contact information.

Has Richard R. Deluca been buying or selling shares of Merck & Co., Inc.?

Richard R. Deluca has not been actively trading shares of Merck & Co., Inc. within the last three months. Most recently, Richard R. Deluca sold 43,823 shares of the business's stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a transaction totalling $4,602,729.69. Following the completion of the sale, the executive vice president now directly owns 111,764 shares of the company's stock, valued at $11,738,572.92. Learn More on Richard R. Deluca's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, insiders at the sold shares 6 times. They sold a total of 106,348 shares worth more than $12,299,065.07. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 2/13/2024.

Richard R. Deluca Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2023Sell43,823$105.03$4,602,729.69111,764View SEC Filing Icon  
5/1/2023Sell75,436$116.03$8,752,839.08154,493View SEC Filing Icon  
4/28/2023Sell66,163$115.00$7,608,745.00154,493View SEC Filing Icon  
10/28/2022Sell164,557$100.26$16,498,484.82136,977View SEC Filing Icon  
11/4/2021Sell29,782$90.40$2,692,292.80View SEC Filing Icon  
10/29/2021Sell135,405$87.56$11,856,061.80View SEC Filing Icon  
8/9/2019Sell6,427$85.09$546,873.43103,223View SEC Filing Icon  
5/3/2019Sell35,000$80.00$2,800,000.00106,064View SEC Filing Icon  
10/30/2018Sell25,467$72.00$1,833,624.0082,135View SEC Filing Icon  
See Full Table

Richard R. Deluca Buying and Selling Activity at Merck & Co., Inc.

This chart shows Richard R Deluca's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $130.56
Low: $129.11
High: $131.20

50 Day Range

MA: $128.85
Low: $124.47
High: $131.84

2 Week Range

Now: $130.56
Low: $99.14
High: $133.10

Volume

17,175,463 shs

Average Volume

8,121,030 shs

Market Capitalization

$330.68 billion

P/E Ratio

145.07

Dividend Yield

2.41%

Beta

0.39